Itau Unibanco Holding S.A. Invests $75,000 in Moderna, Inc. (NASDAQ:MRNA)

Itau Unibanco Holding S.A. acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 629 shares of the company’s stock, valued at approximately $75,000.

A number of other institutional investors have also recently added to or reduced their stakes in MRNA. Ashton Thomas Private Wealth LLC acquired a new position in shares of Moderna during the second quarter valued at $26,000. Cedar Wealth Management LLC grew its stake in shares of Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares in the last quarter. Westside Investment Management Inc. acquired a new position in shares of Moderna during the first quarter valued at $32,000. Family Firm Inc. bought a new stake in shares of Moderna during the second quarter valued at about $33,000. Finally, Rise Advisors LLC lifted its holdings in Moderna by 953.3% in the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after purchasing an additional 286 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $117.08, for a total transaction of $1,756,200.00. Following the completion of the transaction, the director now directly owns 2,269,015 shares in the company, valued at approximately $265,656,276.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. The disclosure for this sale can be found here. Insiders sold 93,158 shares of company stock valued at $11,167,312 over the last ninety days. Corporate insiders own 15.70% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on MRNA. HSBC upgraded shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price target on the stock in a research report on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and cut their target price for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. Hsbc Global Res upgraded Moderna from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 28th. TD Cowen cut their price objective on Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a report on Friday, September 13th. Finally, JPMorgan Chase & Co. cut Moderna from a “neutral” rating to an “underweight” rating and decreased their target price for the company from $88.00 to $70.00 in a research note on Friday, September 13th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $100.44.

Moderna Stock Performance

Shares of MRNA opened at $65.69 on Monday. The company has a market capitalization of $25.18 billion, a PE ratio of -4.19 and a beta of 1.67. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The company’s 50 day moving average price is $90.07 and its 200 day moving average price is $110.96. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter last year, the firm earned ($3.62) earnings per share. The business’s revenue for the quarter was down 29.9% on a year-over-year basis. Research analysts expect that Moderna, Inc. will post -9.52 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.